Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

4D Molecular Therapeutics (FDMT) Invested Capital: 2019-2025

Historic Invested Capital for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $369.0 million.

  • 4D Molecular Therapeutics' Invested Capital fell 33.27% to $369.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $369.0 million, marking a year-over-year decrease of 33.27%. This contributed to the annual value of $510.6 million for FY2024, which is 65.87% up from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' Invested Capital stood at $369.0 million, which was down 12.33% from $420.9 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Invested Capital high stood at $600.6 million for Q1 2024, and its period low was $218.6 million during Q1 2023.
  • In the last 3 years, 4D Molecular Therapeutics' Invested Capital had a median value of $420.9 million in 2025 and averaged $426.7 million.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Invested Capital soared by 174.72% in 2024, and later slumped by 33.27% in 2025.
  • Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Invested Capital stood at $319.1 million in 2021, then fell by 27.50% to $231.3 million in 2022, then soared by 33.07% to $307.8 million in 2023, then spiked by 65.87% to $510.6 million in 2024, then plummeted by 33.27% to $369.0 million in 2025.
  • Its last three reported values are $369.0 million in Q3 2025, $420.9 million for Q2 2025, and $469.7 million during Q1 2025.